City of Hope Acquiring Cancer Treatment Centers of America

Dec. 13, 2021

The CTCA acquisition is part of a broader expansion strategy for Duarte, Calif.-based City of Hope, including launch of AccessHope to extend the reach of its clinical and research expertise directly to employers

David Raths

City of Hope, a National Cancer Institute (NCI)-designated comprehensive cancer research and treatment organization, has agreed to acquire Cancer Treatment Centers of America (CTCA), a network of oncology hospitals and outpatient care centers across the United States.

The transaction is expected to close in early 2022, subject to regulatory approvals. After close, City of Hope intends to convert CTCA to a nonprofit organization.

The combined organization will be one of the largest cancer research and treatment organizations in the country with one of the largest geographic footprints, serving approximately 115,000 patients each year. Combined, City of Hope and CTCA will include approximately 11,000 employees with 575 physicians across a network of locations in California, including a new campus in Irvine opening in summer 2022, as well as Arizona, Illinois and Georgia.

The CTCA acquisition is part of a broader expansion strategy for Duarte, Calif.-based City of Hope. In addition to the ongoing expansion of its clinical network in Southern California, City of Hope previously acquired Translational Genomics Research Institute (TGen), which provides breakthrough genomics research. In 2019, City of Hope launched AccessHope to extend the reach of its clinical and research expertise directly to employers, including 17 of the Fortune 500 companies, so they can provide their employees with cancer information and expert clinical decision support.

“This is a defining moment in the fight against cancer and a powerful opportunity to reach more cancer patients with the leading treatments, care and advanced research they critically need,” said Robert Stone, president and CEO of City of Hope and the Helen and Morgan Chu Chief Executive Officer Distinguished Chair, in a statement. “CTCA has a strong commitment to patient-centric cancer care, and combining its network and services with City of Hope’s scientific expertise, clinical trials and patient care strengths will significantly increase the number of people who can access the latest lifesaving treatments.”

Pat Basu, M.D., M.B.A, president and CEO of CTCA, will remain CEO of CTCA and report to Robert Stone.